Clinical Scorecard: ASCO 2026: AI Challenges a Breast Cancer Standard

At a Glance

Key Highlights

• Artera breast model includes digital pathology and clinical variables.
• FDA-cleared and CE-marked risk stratification tool.
• Study involved over 300 patients with early-stage breast cancer.
• Artera AI tool shows additional prognostic value over the 21-gene recurrence score.
• Significant differences in 10-year distant metastasis rates based on score concordance.

Guideline-Based Recommendations

Diagnosis

• Utilize the Artera AI tool for risk stratification in early-stage breast cancer.

Management

• Consider the prognostic information from the Artera AI tool in treatment decisions.

Monitoring & Follow-up

• Monitor patients with discordant scores for higher distant metastasis rates.

Risks

• Higher 10-year distant metastasis rates observed in patients with discordant scores.

Patient & Prescribing Data

Patients with ER positive, HER2 negative early-stage breast cancer.

Majority of patients in the study did not receive chemotherapy.

Clinical Best Practices

• Incorporate multimodal AI tools in clinical practice for better prognostic assessment.
• Evaluate both Artera scores and 21-gene recurrence scores for comprehensive risk stratification.

Related Resources & Content

• ASCO 2026 Presentation by Dr. Nancy Lin